PT-141

PT-141, known pharmaceutically as Bremelanotide (brand name Vyleesi), is a cyclic heptapeptide melanocortin receptor agonist. It is derived from Melanotan II through structural modification to reduce unwanted melanogenic (skin-darkening) activity while retaining sexual arousal effects. Developed initially by Palatin Technologies, Bremelanotide received FDA approval in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few peptides discussed in this resource with formal FDA approval.

The drug's approval was based on two Phase III clinical trials (RECONNECT trials) demonstrating statistically significant improvements in desire and reductions in distress related to low sexual desire. It was FDA-approved under the brand name Vyleesi, marketed by AMAG Pharmaceuticals (later acquired by Covis Pharma).

What distinguishes PT-141 from other sexual health treatments is its central mechanism of action: rather than affecting blood flow to genital tissues (as sildenafil/Viagra does), PT-141 acts on melanocortin receptors in the brain to modulate sexual desire, arousal, and motivation at the neurological level. This makes it potentially effective for both men and women and for cases where the root cause is neurological/psychological rather than vascular.

While Vyleesi is FDA-approved specifically for premenopausal women with HSDD, PT-141 is also used off-label in men for erectile dysfunction and libido, particularly in cases where PDE5 inhibitors (Viagra, Cialis) are ineffective or contraindicated.

PT-141 works through melanocortin receptor activation in the central nervous system:

• Melanocortin receptor agonism: PT-141 activates MC3R (melanocortin 3 receptor) and MC4R (melanocortin 4 receptor) in the brain and spinal cord. These receptors are involved in regulating sexual arousal, motivation, and desire through hypothalamic and limbic system pathways.
• Central (CNS) mechanism: Unlike sildenafil (Viagra) and similar drugs that primarily affect penile/clitoral blood flow through PDE5 inhibition, PT-141 acts centrally in the brain to increase sexual motivation and desire at the neurological level. This central action may explain its potential effectiveness in cases of low desire (HSDD) rather than purely vascular dysfunction.
• Dopaminergic modulation: Melanocortin signaling in the brain interacts with dopaminergic pathways associated with reward, motivation, and pleasure — systems fundamentally involved in sexual desire.
• Oxytocin release: Some research suggests melanocortin receptor activation promotes oxytocin release, which is associated with bonding, trust, and sexual receptivity.
• Reduced melanogenic activity: PT-141 was structurally modified from Melanotan II to reduce activation of MC1R (the primary melanocyte receptor responsible for skin pigmentation), minimizing skin-darkening side effects while retaining MC3R/MC4R activity.

PT-141's benefits are supported by clinical trial data for its approved indication:

• Increased sexual desire in HSDD: FDA approval is based on RECONNECT Phase III trials showing statistically significant improvements in the number of satisfying sexual events and reductions in distress due to low desire in premenopausal women with HSDD.
• Rapid onset: PT-141 typically begins working within 45–90 minutes of subcutaneous injection, making it a practical on-demand treatment.
• Male erectile function: Off-label use in men suggests PT-141 can improve erectile function and libido, particularly in cases of psychogenic erectile dysfunction or where desire/motivation (rather than vascular function) is the limiting factor. Some men who do not respond adequately to PDE5 inhibitors report benefit from PT-141.
• Central arousal enhancement: By acting on brain desire mechanisms rather than peripheral blood flow, PT-141 may address sexual dysfunction with a psychological or neurological component that vascular drugs cannot address.
• Duration of effect: Effects typically last 6–12 hours after a single dose.

PT-141's side effects are well-characterized from clinical trials given its FDA-approved status:

• Nausea: The most commonly reported and dose-limiting side effect; occurred in approximately 40% of subjects in clinical trials. Often mild-to-moderate but can be significant enough to limit use at higher doses.
• Flushing: Hot flush/facial flushing is common (approximately 20% in trials), related to vasodilatory effects of melanocortin signaling.
• Headache: Reported in approximately 11% of subjects in the RECONNECT trials.
• Injection site reactions: Local discomfort, redness, or bruising at the subcutaneous injection site.
• Hyperpigmentation: Despite efforts to reduce melanogenic activity, some skin darkening was reported with repeated use; particularly noted on the face and in people with darker skin tones.
• Blood pressure changes: Transient increases in blood pressure have been reported; PT-141 is contraindicated in patients with cardiovascular disease or high blood pressure risk due to this effect.
• Yawning/fatigue: Mediated through hypothalamic melanocortin and oxytocin pathways; common especially at higher doses.

FDA-approved labeling for Vyleesi includes cardiovascular contraindications and recommendations against use with certain medications. Always review the full prescribing information with a healthcare provider.

PT-141 has an established FDA-approved dosing regimen for its approved indication:

• FDA-approved dose (Vyleesi for HSDD): 1.75 mg administered as a subcutaneous injection into the abdomen or thigh, approximately 45 minutes before anticipated sexual activity; maximum one dose per 24 hours; no more than one dose per day
• Off-label male use: Research community protocols for men typically reference 0.5–2 mg subcutaneous injection; the lower end of this range is often preferred to minimize side effects
• Titration approach: Due to nausea risk, many practitioners recommend starting at lower doses (0.5–1 mg) and increasing as tolerated
• Anti-nausea pre-treatment: Some protocols suggest taking an antiemetic (e.g., ondansetron) 30 minutes before PT-141 injection to reduce nausea risk

Unlike many research peptides that require daily administration, PT-141 is used on-demand, which limits cumulative exposure and may reduce long-term side effect concerns.

PT-141 has a robust clinical evidence base given its FDA-approved status:

• RECONNECT Phase III trials: Two large randomized controlled trials in premenopausal women with HSDD demonstrated statistically significant improvements in satisfying sexual events and desire-related distress with PT-141 versus placebo, supporting FDA approval.
• Male erectile dysfunction studies: Earlier Phase II studies in men with erectile dysfunction showed improvements in erectile function, particularly in psychogenic ED where desire and motivation are primary issues. These studies preceded the decision to focus development on female HSDD.
• Melanotan II predecessor: PT-141 was developed from Melanotan II research, which showed strong pro-sexual effects but also significant skin-darkening and nausea. The structural modifications in PT-141 aimed to preserve sexual activity while reducing these unwanted effects.
• Neuroscience research: Basic science research on melanocortin receptors in sexual behavior (primarily in animal models) provided mechanistic understanding of how MC3R and MC4R activation drives sexual arousal, supporting the target selection for PT-141.

PT-141/Bremelanotide represents one of the success stories in peptide pharmaceutical development — a research peptide that proceeded through the full FDA approval process and reached the market.